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analytical sample contained 26,349 admissions: 762 stays
involved mechanical ventilation, 9495 had ICU time, and 16,092
had neither. Hospital mortality rates were 27.7%, 23.8% and
7.6% for these three groups, respectively. Median cost per stay
was substantially higher for those with ventilation ($39,493)
versus those with ICU time but no ventilation ($25,798) and
those with neither ($7261). Average length of stay in the ICU
was 14 days and 9 days for those with and without ventilation,
respectively. Average anti-infective drug costs were 1.79 times
higher in the ventilator group compared with the ICU group.
CONCLUSION: VAP is an area of high unmet need. Among
these 1500 hospitals, 2003 costs for those with mechanical ven-
tilation were 1.5 times higher than a group of NP cases that were
fairly complex, as indicated by some receipt of intensive care 
services.
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OBJECTIVE: To estimate lifetime medical cost of chronic hepati-
tis B in the United States from the societal perspective.
METHODS: A hypothetical 35-year old cohort of 100,000 indi-
viduals with chronic hepatitis B was tracked in a Markov model
of the natural history of disease. The model assumed standard
clinical care for disease complications, but did not include antivi-
ral treatment. Disease outcomes modeled included cirrhosis,
hepatocellular carcinoma, liver transplantation and death.
Annual transition parameters were estimated from long-term
disease progression data in the literature. Outcome speciﬁc cost
data were derived from published studies and the MarketScan®
database. Expected lifetime medical cost was determined as the
sum of weighted average medical cost of health outcomes over
the cohort lifetime discounted at 3% annual rate and adjusted
to 2005 U.S. dollars. Impact of variations in model parameters
was assessed in one-way sensitivity analyses. RESULTS: The
expected per patient lifetime medical cost of chronic hepatitis B
for the 35-year old cohort was $34,760 (range in sensitivity
analyses: $9367−$59,298). About 73% of the cost was for cir-
rhosis, 10% for hepatocellular carcinoma and 11% for liver
transplantation. The cost varied with the initial age at infection
of the cohort: for a cohort aged 25 years at infection, the cost
was 11% more than the cost for the 35-year olds, and for a 
45-year old cohort, the cost was 16% less than the cost for the
35-year olds. The cost estimate was most sensitive to the annual
rate of developing compensated cirrhosis. CONCLUSIONS:
Life-time medical cost of a chronic hepatitis B patient is sub-
stantial. Identiﬁcation of the disease at early stage for anti-
viral treatment could reduce the likelihood of developing end-
stage liver diseases and avert higher costs.
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OBJECTIVE: To evaluate the economic implications of upper
respiratory tract infection to the Nigerian society. METHODS:
It involves Cost of Illness analysis among upper respiratory tract
infection Out- Patients in Lagos University Teaching Hospital.
Data collected from 182 case notes include; demographics, diag-
nosis, diagnostic tests, no of visits, and prescribed drugs. Direct
and indirect costs were included. The costs include, personnel,
diagnostic tests, transport and antibacterial cost. The hospital
cost of drugs and tests were used. Stop-watch time studies and
monthly earnings were used to calculate the personnel costs.
Average time spent at each visit and expected earnings were used
to calculate the indirect costs. The current hospital costs were
used for all calculations hence neither discounting nor inﬂation
was considered. RESULTS: Total cost of drugs = N358,790.00
($2462.80); Average = N1971.40 ($14.10) Personnel cost =
N49,156.40 ($351.12); Average = N270.00 ($1.93) Diagnostic
Test cost = N9100.00 ($65.00); Average = N50.00 ($0.36) Trans-
port cost = N36,930.00 ($263.80); Average = N202.91 ($1.45)
Indirect cost = N103,350.00 ($738.21) Average = N567.86
($4.06) Cost of illness = N557,326.40 ($3981.10) Average =
N3062.23 ($21.87). Cost of drugs for each disease condition
Acute Otitis media (n = 45 = N24, 526.00 ($175.20); Average =
N545.02 ($3.90). Chronic Superative Otitis media (n = 37) = N
42,982.00 ($307.01); Average = N1161.68 ($8.30) onchopneu-
monia (n = 70) = N257, 299.00 ($1837.85); Average = N
3675.41 ($26.25) Tonsilitis (n = 12) = N14, 923.00 ($106.60);
Average = N1243.58 ($8.90). Other) = N19060.00 ($136.14);
Average = N1058.94 ($7.56). Prevalence of Otitis media in
Nigeria = 29.0% in children below 5 years. = 7,772,000 cases
(7.7million cases) Average cost of Otitis media = N823.27
($5.88) Cost of drugs for 7.7 million cases of otitis media alone
= N6, 398,454,440.00 (Over N6.3 billion) (>$450million).
CONCLUSION: Cost of therapy associated with URTI is enor-
mous. This high cost might be partly due to the use of antibi-
otics in most cases of URTI, a good proportion of which are
viral. The use of treatment guidelines is necessary to ensure a
wise use of the limited resources.
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OBJECTIVES: To estimate direct medical costs associated to
adult patients with HIV/AIDS in second and third level hospitals
in the Social Security Mexican Institute. METHODS: Partial eco-
nomic evaluation was performed employing a one-year survey to
identify patients with HIV/AIDS resource use. The study revised
hospital records in 8 second level hospitals and 2 third level hos-
pitals in Mexico City throughout 2003. Resource use estimates
include outpatient and inpatients services (visits to physicians or
specialists, laboratory and gabinet exams, medications, emer-
gency services, hospitalization, etc.). The research estimates total
direct medical costs and average costs per patient per year. The
analysis was conducted from the healthcare payer’s perspective.
All costs were expressed in 2005 US$. RESULTS: A total of 1969
adult patients with HIV/AIDS were recruited with an average age
of 39 ± 10 years; 86.4% were male. The evolution average time
with HIV was of 6 ± 3 years. 29% of patients were in clinical
stage A; 26% in clinical stage B and 45% in clinical stage C. The
total direct medical cost of these patients on a 1-year follow up
was US$1.107.952,58. Eighty-eight percent of this amount cor-
responds to antiretroviral drugs, 10% to physician’s or special-
ists visits and 2% to non-antiretroviral drugs and laboratory
exams. A total of 9.6% of the sample required inpatient services
with a mean cost per patient of US$ 3103.2. Outpatient services
had an annual mean cost per patient of US$ 5665.1 and the
annual expected cost per patient in the Social Security Mexican
Institute was estimated in US$ 5964.6. CONCLUSIONS: Eco-
nomic consequences of HIV/AIDS patients are substantial for the
Mexican Health Budget, especially due to antiretroviral drugs.
